1028252-15-4

Usage

Uses

Used in Pharmaceutical Research and Development:
1,2-Pyrrolidinedicarboxylic acid, 4-[(7-chloro-4-Methoxy-1-isoquinolinyl)oxy]-, 1-(1,1-diMethylethyl) ester, (2S,4R)is used as a key intermediate in the synthesis of new drugs or medical treatments. Its unique molecular structure and functional groups make it a promising candidate for the development of innovative pharmaceuticals.
Used in Drug Delivery Systems:
1,2-Pyrrolidinedicarboxylic acid, 4-[(7-chloro-4-Methoxy-1-isoquinolinyl)oxy]-, 1-(1,1-diMethylethyl) ester, (2S,4R)-'s 1,1-diMethylethyl ester group suggests potential applications in drug delivery or formulation. It can be utilized to improve the solubility, stability, or bioavailability of active pharmaceutical ingredients, enhancing their therapeutic efficacy and safety.
Used in Medicinal Chemistry:
The presence of the 7-chloro-4-methoxy-1-isoquinolinyl group in the molecule indicates its potential use in medicinal chemistry for the design and optimization of novel drug candidates. This group may contribute to the compound's biological activity, selectivity, and pharmacokinetic properties.

Upstream product

• 630423-36-8 1,7-dichloro-4-methoxyisoquinoline 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 1028252-13-2 4-bromo-7-chloroisoquinolin-1-ol 
• 24188-74-7 7-chloroisoquinolin-1-ol 
• 1615-02-7 p-chlorocinnamic acid 
• 1028252-13-2 4-bromo-7-chloro-2H-isoquinolin-1-one 
• 1028252-14-3 1,7-dichloroisoquinolin-4-ol 
• 953421-74-4 4-bromo-1,7-dichloroisoquinoline 
• 24188-74-7 7-chloroisoquinoline-1(2Η)-one 
• 26386-88-9 diphenyl phosphoryl azide 

Downstream Products

• 630420-16-5 tert-butyl ((S)-1-((2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 
• 1169846-35-8 (2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride 

Relevant academic research and scientific papers

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection

The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis C virus infection. The discovery of 24 was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chemical series, BMS-605339 (1), from clinical trials. The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the molecule had a significant impact on the CV profile of a given compound. The antiviral activity, preclincial PK profile, and toxicology studies in rat and dog supported clinical development of BMS-650032 (24).

TRIPEPTIDES INCORPORATING DEUTERIUM AS INHIBITORS OF HEPATITIS C VIRUS

Hepatitis C virus inhibitors having the general formula (I) [INSERT CHEMICAL STRUCTURE HERE] are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCLOPROPYL)-L-PROLINAMIDE

The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.